Methylphenidate and cocaine: the same effects on gene regulation?

Trends in Pharmacological Sciences

Volumn 28, Issue 11, 2007, Pages 588-596

  Yano, Motoyo ^a   Steiner, Heinz ^a  

^a ROSALIND FRANKLIN UNIVERSITY OF MEDICINE AND SCIENCE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMPHETAMINE; BRAIN DERIVED NEUROTROPHIC FACTOR; COCAINE; CYCLIC AMP RESPONSIVE ELEMENT BINDING PROTEIN; DOPAMINE 2 RECEPTOR; DYNORPHIN; ENKEPHALIN; METHYLPHENIDATE; NEUROTRANSMITTER; SUBSTANCE P; TRANSCRIPTION FACTOR; TRANSCRIPTION FACTOR FOSB; VESICULAR MONOAMINE TRANSPORTER 2;

ADDICTION; ANIMAL BEHAVIOR; ATTENTION DEFICIT DISORDER; BEHAVIOR; BEHAVIOR CHANGE; BRAIN REGION; CORPUS STRIATUM; DRUG SELF ADMINISTRATION; GENE CONTROL; HUMAN; LONG TERM CARE; NERVE CELL; NERVE CELL PLASTICITY; NONHUMAN; ONCOGENE C FOS; POSTSYNAPTIC POTENTIAL; PRIORITY JOURNAL; PROTEIN EXPRESSION; REVIEW; RNA SPLICING; SIGNAL TRANSDUCTION; TREATMENT DURATION;

AMPHETAMINE; ANIMALS; CENTRAL NERVOUS SYSTEM STIMULANTS; COCAINE; CORPUS STRIATUM; GENE EXPRESSION REGULATION; HUMANS; METHYLPHENIDATE; MOLECULAR STRUCTURE;

EID: 35648994792     PISSN: 01656147     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.tips.2007.10.004     Document Type: Review

References (90)

1. Diagnostic and Statistical Manual of Mental Disorders, Fourth Edition (2000) American Psychiatric Association
2. Robison L.M., et al. National trends in the prevalence of attention-deficit/hyperactivity disorder and the prescribing of methylphenidate among school-age children: 1990-1995. Clin. Pediatr. (Phila.) 38 (1999) 209-217
3. Biederman J., et al. Diagnosis and treatment of adults with attention-deficit/hyperactivity disorder. CNS Spectr. 12 (2007) 1-15
4. Zito J.M., et al. Trends in the prescribing of psychotropic medications to preschoolers. J. Am. Med. Assoc. 283 (2000) 1025-1030
5. Carlezon W.A.J., and Konradi C. Understanding the neurobiological consequences of early exposure to psychotropic drugs: linking behavior with molecules. Neuropharmacology 47 (2004) 47-60
6. Andersen S.L. Stimulants and the developing brain. Trends Pharmacol. Sci. 26 (2005) 237-243
7. Kollins S.H., et al. Assessing the abuse potential of methylphenidate in nonhuman and human subjects: a review. Pharmacol. Biochem. Behav. 68 (2001) 611-627
8. Babcock Q., and Byrne T. Student perceptions of methylphenidate abuse at a public liberal arts college. J. Am. Coll. Health 49 (2000) 143-145
9. Teter C.J., et al. Illicit use of specific prescription stimulants among college students: prevalence, motives, and routes of administration. Pharmacotherapy 26 (2006) 1501-1510
10. White B.P., et al. Stimulant medication use, misuse, and abuse in an undergraduate and graduate student sample. J. Am. Coll. Health 54 (2006) 261-268
11. Parran T.V.J., and Jasinski D.R. Intravenous methylphenidate abuse. Prototype for prescription drug abuse. Arch. Intern. Med. 151 (1991) 781-783
12. Adriani W., et al. Methylphenidate administration to adolescent rats determines plastic changes in reward-related behavior and striatal gene expression. Neuropsychopharmacology 31 (2006) 1946-1956
13. Adriani W., et al. Short-term effects of adolescent methylphenidate exposure on brain striatal gene expression and sexual/endocrine parameters in male rats. Ann. N. Y. Acad. Sci. 1074 (2006) 52-73
14. Gerfen C.R., and Wilson C.J. The basal ganglia. In: Swanson L.W., et al. (Ed). Handbook of Chemical Neuroanatomy (1996), Elsevier 371-468
15. Berke J.D., and Hyman S.E. Addiction, dopamine, and the molecular mechanisms of memory. Neuron 25 (2000) 515-532
16. Yano M., and Steiner H. Methylphenidate (Ritalin) induces Homer 1a and zif 268 expression in specific corticostriatal circuits. Neuroscience 132 (2005) 855-865
17. Yano M., and Steiner H. Topography of methylphenidate (Ritalin)-induced gene regulation in the striatum: differential effects on c-fos, substance P and opioid peptides. Neuropsychopharmacology 30 (2005) 901-915
18. Willuhn I., et al. Topography of cocaine-induced gene regulation in the rat striatum: Relationship to cortical inputs and role of behavioural context. Eur. J. Neurosci. 17 (2003) 1053-1066
19. Robbins T.W., et al. Neural systems underlying arousal and attention. Implications for drug abuse. Ann. N. Y. Acad. Sci. 846 (1998) 222-237
20. Solanto M.V. Dopamine dysfunction in AD/HD: integrating clinical and basic neuroscience research. Behav. Brain Res. 130 (2002) 65-71
21. Carlezon W.A.J., et al. The many faces of CREB. Trends Neurosci. 28 (2005) 436-445
22. Harlan R.E., and Garcia M.M. Drugs of abuse and immediate-early genes in the forebrain. Mol. Neurobiol. 16 (1998) 221-267
23. McClung C.A., et al. DeltaFosB: a molecular switch for long-term adaptation in the brain. Brain Res. Mol. Brain Res. 132 (2004) 146-154
24. Steiner H., and Gerfen C.R. Role of dynorphin and enkephalin in the regulation of striatal output pathways and behavior. Exp. Brain Res. 123 (1998) 60-76
25. Wang J.Q., and McGinty J.F. Glutamatergic and cholinergic regulation of immediate-early gene and neuropeptide gene expression in the striatum. In: Merchant K.M. (Ed). Pharmacological Regulation of Gene Expression in the CNS (1996), CRC 81-113
26. Lin J.S., et al. Potential brain neuronal targets for amphetamine-, methylphenidate-, and modafinil-induced wakefulness, evidenced by c-fos immunocytochemistry in the cat. Proc. Natl. Acad. Sci. U. S. A. 93 (1996) 14128-14133
27. Brandon C.L., and Steiner H. Repeated methylphenidate treatment in adolescent rats alters gene regulation in the striatum. Eur. J. Neurosci. 18 (2003) 1584-1592
28. Chase T.D., et al. Daily methylphenidate administration attenuates c-fos expression in the striatum of prepubertal rats. Neuroreport 14 (2003) 769-772
29. Penner M.R., et al. Age-related distribution of c-fos expression in the striatum of CD-1 mice after acute methylphenidate administration. Brain Res. Dev. Brain Res. 135 (2002) 71-77
30. Trinh J.V., et al. Differential psychostimulant-induced activation of neural circuits in dopamine transporter knockout and wild type mice. Neuroscience 118 (2003) 297-310
31. Yano M., et al. Inhibition of methylphenidate-induced gene expression in the striatum by local blockade of D1 dopamine receptors: Interhemispheric effects. Neuroscience 140 (2006) 699-709
32. Chase T.D., et al. Methylphenidate regulates c-fos and fosB expression in multiple regions of the immature rat brain. Brain Res. Dev. Brain Res. 156 (2005) 1-12
33. Andersen S.L., et al. Maturational increases in c-fos expression in the ascending dopamine systems. Synapse 41 (2001) 345-350
34. Ehrlich M.E., et al. Periadolescent mice show enhanced DeltaFosB upregulation in response to cocaine and amphetamine. J. Neurosci. 22 (2002) 9155-9199
35. Hope B., et al. Regulation of immediate early gene expression and AP-1 binding in the rat nucleus accumbens by chronic cocaine. Proc. Natl. Acad. Sci. U. S. A. 89 (1992) 5764-5768
36. Steiner H., and Gerfen C.R. Cocaine-induced c-fos messenger RNA is inversely related to dynorphin expression in striatum. J. Neurosci. 13 (1993) 5066-5081
37. Chase T.D., et al. Methylphenidate differentially regulates c-fos and fosB expression in the developing rat striatum. Dev. Brain Res. 157 (2005) 181-191
38. Cotterly L., et al. Dysregulation of gene induction in corticostriatal circuits after repeated methylphenidate treatment in adolescent rats: Differential effects on zif 268 and homer 1a. Eur. J. Neurosci. 25 (2007) 3617-3628
39. Andersen S.L., et al. Altered responsiveness to cocaine in rats exposed to methylphenidate during development. Nat. Neurosci. 5 (2002) 13-14
40. Hurd Y.L., and Herkenham M. Molecular alterations in the neostriatum of human cocaine addicts. Synapse 13 (1993) 357-369
41. Hurd Y.L., and Herkenham M. Influence of a single injection of cocaine, amphetamine or GBR 12909 on mRNA expression of striatal neuropeptides. Brain Res. Mol. Brain Res. 16 (1992) 97-104
42. Smith A.J.W., and McGinty J.F. Acute amphetamine or methamphetamine alters opioid peptide mRNA expression in rat striatum. Brain Res. Mol. Brain Res. 21 (1994) 359-362
43. Wang J.Q., et al. A single injection of amphetamine or methamphetamine induces dynamic alterations in c-fos, zif/268 and preprodynorphin messenger RNA expression in rat forebrain. Neuroscience 68 (1995) 83-95
44. Wang J.Q., and McGinty J.F. D1 and D2 receptor regulation of preproenkephalin and preprodynorphin mRNA in rat striatum following acute injection of amphetamine or methamphetamine. Synapse 22 (1996) 114-122
45. Daunais J.B., and McGinty J.F. Acute and chronic cocaine administration differentially alters striatal opioid and nuclear transcription factor mRNAs. Synapse 18 (1994) 35-45
46. Spangler R., et al. Prodynorphin, proenkephalin and kappa opioid receptor mRNA responses to acute "binge" cocaine. Brain Res. Mol. Brain Res. 44 (1997) 139-142
47. Sandoval V., et al. Methylphenidate redistributes vesicular monoamine transporter-2: role of dopamine receptors. J. Neurosci. 22 (2002) 8705-8710
48. Moll G.H., et al. Early methylphenidate administration to young rats causes a persistent reduction in the density of striatal dopamine transporters. J. Child Adolesc. Psychopharmacol. 11 (2001) 15-24
49. Izenwasser S., et al. Chronic methylphenidate alters locomotor activity and dopamine transporters differently from cocaine. Eur. J. Pharmacol. 373 (1999) 187-193
50. Pascoli V., et al. cAMP and extracellular signal-regulated kinase signaling in response to d-amphetamine and methylphenidate in the prefrontal cortex in vivo: role of beta 1-adrenoceptors. Mol. Pharmacol. 68 (2005) 421-429
51. Xiao B., et al. Homer: a link between neural activity and glutamate receptor function. Curr. Opin. Neurobiol. 10 (2000) 370-374
52. Thomas U. Modulation of synaptic signalling complexes by Homer proteins. J. Neurochem. 81 (2002) 407-413
53. Fukui R., et al. Effect of methylphenidate on dopamine/DARPP signalling in adult, but not young, mice. J. Neurochem. 87 (2003) 1391-1401
54. Crawford C.A., et al. Repeated methylphenidate treatment induces behavioral sensitization and decreases protein kinase A and dopamine-stimulated adenylyl cyclase activity in the dorsal striatum. Psychopharmacology (Berl.) 136 (1998) 34-43
55. Schweri M.M., et al. [3H]Threo-(+/-)-methylphenidate binding to 3,4-dihydroxyphenylethylamine uptake sites in corpus striatum: correlation with the stimulant properties of ritalinic acid esters. J. Neurochem. 45 (1985) 1062-1070
56. Gatley S.J., et al. Affinities of methylphenidate derivatives for dopamine, norepinephrine and serotonin transporters. Life Sci. 58 (1996) 231-239
57. Kuczenski R., and Segal D.S. Effects of methylphenidate on extracellular dopamine, serotonin, and norepinephrine: comparison with amphetamine. J. Neurochem. 68 (1997) 2032-2037
58. Kankaanpaa A., et al. 5-HT3 receptor antagonist MDL 72222 attenuates cocaine- and mazindol-, but not methylphenidate-induced neurochemical and behavioral effects in the rat. Psychopharmacology (Berl.) 159 (2002) 341-350
59. Muller C.P., and Huston J.P. Determining the region-specific contributions of 5-HT receptors to the psychostimulant effects of cocaine. Trends Pharmacol. Sci. 27 (2006) 105-112
60. Bhat R.V., and Baraban J.M. Activation of transcription factor genes in striatum by cocaine: role of both serotonin and dopamine systems. J. Pharmacol. Exp. Ther. 267 (1993) 496-505
61. Gardier A.M., et al. Interaction between the serotoninergic and dopaminergic systems in d-fenfluramine-induced activation of c-fos and jun B genes in rat striatal neurons. J. Neurochem. 74 (2000) 1363-1373
62. Walker P.D., et al. Preprotachykinin and preproenkephalin mRNA expression within striatal subregions in response to altered serotonin transmission. Brain Res. 732 (1996) 25-35
63. Mijnster M.J., et al. Serotonergic regulation of neuropeptide and glutamic acid decarboxylase mRNA levels in the rat striatum and globus pallidus: studies with fluoxetine and DOI. Brain Res. Mol. Brain Res. 54 (1998) 64-73
64. Horner K.A., et al. Blockade of stimulant-induced preprodynorphin mRNA expression in the striatal matrix by serotonin depletion. Neuroscience 131 (2005) 67-77
65. Borycz, J. et al. 5-HT(1B) Receptor-mediated serotoninergic modulation of methylphenidate-induced locomotor activation in rats. Neuropsychopharmacology DOI: 10.1038/sj.npp.1301445 (http://www.nature.com/npp/index.html)
66. Hyman S.E., and Nestler E.J. Initiation and adaptation: a paradigm for understanding psychotropic drug action. Am. J. Psychiatry 153 (1996) 151-162
67. Samaha A.N., and Robinson T.E. Why does the rapid delivery of drugs to the brain promote addiction?. Trends Pharmacol Sci. 26 (2005) 82-87
68. Gerasimov M.R., et al. Comparison between intraperitoneal and oral methylphenidate administration: A microdialysis and locomotor activity study. J. Pharmacol. Exp. Ther. 295 (2000) 51-57
69. Chase T., et al. Methylphenidate regulates activity regulated cytoskeletal associated but not brain-derived neurotrophic factor gene expression in the developing rat striatum. Neuroscience 144 (2007) 969-984
70. Swanson J.M., and Volkow N.D. Serum and brain concentrations of methylphenidate: implications for use and abuse. Neurosci. Biobehav. Rev. 27 (2003) 615-621
71. Kuczenski R., and Segal D.S. Stimulant actions in rodents: implications for attention-deficit/hyperactivity disorder treatment and potential substance abuse. Biol. Psychiatry 57 (2005) 1391-1396
72. Volkow N.D., et al. Therapeutic doses of oral methylphenidate significantly increase extracellular dopamine in the human brain. J. Neurosci. 21(RC121) (2001) 1-5
73. Volkow N.D., et al. Blockade of striatal dopamine transporters by intravenous methylphenidate is not sufficient to induce self-reports of "high". J. Pharmacol. Exp. Ther. 288 (1999) 14-20
74. Spencer T.J., et al. PET study examining pharmacokinetics, detection and likeability, and dopamine transporter receptor occupancy of short- and long-acting oral methylphenidate. Am. J. Psychiatry 163 (2006) 387-395
75. Barkley R.A., et al. Does the treatment of attention-deficit/hyperactivity disorder with stimulants contribute to drug use/abuse? A 13-year prospective study. Pediatrics 111 (2003) 97-109
76. Wilens T.E., et al. Does stimulant therapy of attention-deficit/hyperactivity disorder beget later substance abuse? A meta-analytic review of the literature. Pediatrics 111 (2003) 179-185
77. Schenk S., and Izenwasser S. Pretreatment with methylphenidate sensitizes rats to the reinforcing effects of cocaine. Pharmacol. Biochem. Behav. 72 (2002) 651-657
78. McDougall S.A., et al. Effects of repeated methylphenidate treatment in the young rat: sensitization of both locomotor activity and stereotyped sniffing. Exp. Clin. Psychopharmacol. 7 (1999) 208-218
79. Brandon C.L., et al. Enhanced reactivity and vulnerability to cocaine following methylphenidate treatment in adolescent rats. Neuropsychopharmacology 25 (2001) 651-661
80. Kuczenski R., and Segal D.S. Locomotor effects of acute and repeated threshold doses of amphetamine and methylphenidate: relative roles of dopamine and norepinephrine. J. Pharmacol. Exp. Ther. 296 (2001) 876-883
81. Meririnne E., et al. Rewarding properties of methylphenidate: sensitization by prior exposure to the drug and effects of dopamine D1- and D2-receptor antagonists. J. Pharmacol. Exp. Ther. 298 (2001) 539-550
82. Carlezon W.A.J., et al. Enduring behavioral effects of early exposure to methylphenidate in rats. Biol. Psychiatry 54 (2003) 1330-1337
83. Bolanos C.A., et al. Methylphenidate treatment during pre- and periadolescence alters behavioral responses to emotional stimuli at adulthood. Biol. Psychiatry 54 (2003) 1317-1329
84. Pan D., et al. Binding of bromine-substituted analogs of methylphenidate to monoamine transporters. Eur. J. Neurosci. 264 (1994) 177-182
85. Bymaster F.P., et al. Atomoxetine increases extracellular levels of norepinephrine and dopamine in prefrontal cortex of rat: a potential mechanism for efficacy in attention deficit/hyperactivity disorder. Neuropsychopharmacology 27 (2002) 699-711
86. Hurd Y.L., and Ungerstedt U. In vivo neurochemical profile of dopamine uptake inhibitors and releasers in rat caudate-putamen. Eur. J. Pharmacol. 166 (1989) 251-260
87. Berridge C.W., et al. Methylphenidate preferentially increases catecholamine neurotransmission within the prefrontal cortex at low doses that enhance cognitive function. Biol. Psychiatry 60 (2006) 1111-1120
88. Segal D.S., and Kuczenski R. Escalating dose-binge treatment with methylphenidate: role of serotonin in the emergent behavioral profile. J. Pharmacol. Exp. Ther. 291 (1999) 19-30
89. Hawken C.M., et al. Long-term methylphenidate treatment down-regulates c-fos in the striatum of male CD-1 mice. Neuroreport 15 (2004) 1045-1048
90. Brakeman P.R., et al. Homer: a protein that selectively binds metabotropic glutamate receptors. Nature 386 (1997) 284-288